Genmab — Juni 2025

[E_L]

EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial https://finance.yahoo.com/news/eha-2025-genmab-abbvie-epkinly-134631049.html

[ProinvestorNEWS]

Hej wisuwa...Du kan evt starte med at læse chathistorikken. https://proinvestor.com/chathistory/-25/genmab

[ProinvestorNEWS]

Jyske Bank: Genmab – Positivt nyt fra Epcoritamab https://proinvestor.com/investornyt/1329914/jyske-bank-genmab-positivt-nyt-fra-epcoritamab

[E_L]

España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes https://www.immedicohospitalario.es/noticia/51673/espana-lidera-un-estudio-pionero-con-epcoritamab-para-mejorar-el-abor.html REPIFIR = Response-adaptive to Epcoritamab In FIrst Relapse

[bikube]

UHA, det bliver sjovt at evaluere på. Men den enkelte patients behov må jo komme i første række.

[transalp]

Go morgen..

[E_L]

Presentations & posters for EHA 2025 via https://www.genmabmedicalaffairs.com/congress?filv1=5

[E_L]

EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy. https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge

[E_L]

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant

[E_L]

EHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are ASCT eligible? https://www.youtube.com/watch?v=bCdPlWOjJ1M

[E_L]

RITUXIMAB AND EPCORITAMAB AS FIRST-LINE THERAPY FOR PATIENTS WITH HIGH-TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_227 -from the

18th International Conference on Malignant Lymphoma https://onlinelibrary.wiley.com/toc/10991069/2025/43/S3

[E_L]

Hemab Therapeutics
@Hemab_Tx

ICYMI: Last week we announced the International Non-Proprietary Name (INN) sutacimig for HMB-001 — marking the first-ever INN for a treatment designated for Glanzmann thrombasthenia.https://x.com/Hemab_Tx/status/1935293889662898321

[gentogen]

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress - HealthCap

Sutacimig (formerly HMB-001) continues to demonstrate promising interim safety, PK, and efficacy Phase 2 results in Glanzmann thrombasthenia and is granted its International Non-Proprietary Name designation by WHO HMB-002 shows promise in Von Willebrand disease with initial proof of mechanism clinical data from patients in ongoing VELORA Pioneer study, supported by comprehensive non-clinical package including […]

HealthCap (www.healthcap.eu)

[gentogen]

Interim results show HMB-001 significantly reduces frequency of bleeding events with a favorable safety profile, supporting its potential as a novel prophylactic treatment for GT. HMB-001’s subcutaneous dosing offers a proactive alternative to reactive GT care, addressing a critical unmet need.

[gentogen]

https://s2.goeshow.com/isth/annual/2025/conference_program_sessions.cfm

[transalp]

Go morgen..

[E_L]

The EPCORE NHL-2 trial: epcoritamab plus GemOx in transplant-ineligible R/R DLBCL https://www.youtube.com/watch?v=w1GmTshxnbU

[E_L]

ICML 2025 | Results from EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated DLBCL https://www.youtube.com/watch?v=9sco80a47i4

[E_L]

DARZALEX (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma https://www.globenewswire.com/news-release/2025/06/20/3102621/0/en/DARZALEX-daratumumab-receives-the-first-positive-CHMP-opinion-for-patients-with-high-risk-smouldering-multiple-myeloma.html

[E_L]

Lymphoma Hub
@lymphomahub 18ICML Fixed-duration epcoritamab monotherapy led to high response rates (ORR, 78%; CR rate, 70%) and a manageable safety profile in older, anthracycline-ineligible patients with LBCL. These results suggest that epcoritamab monotherapy is a promising chemotherapy-free treatment option for this patient population. https://x.com/lymphomahub/status/1935994273180025220